Singapore, March 10 -- Pfizer Japan Inc., and ASKA Pharmaceutical have announced that they will begin co-promotion of the Respiratory Syncytial Virus (RSV) vaccine "ABRYSVO(R) intramuscular injection", in Japan starting April 1, 2026.
Published by HT Digital Content Services with permission from BioSpectrum Asia....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.